Tavoron Strengthens Industrial Automation Portfolio with Acquisition of Fluidraulics

Tavoron Expands Automation Capabilities with Acquisition of Fluidraulics Tavoron, a national leader in industrial automation, robotics, compressed air, motion control and engineered solutions, announced the acquisition of Fluidraulics Inc., an automation component and system distributor that has served customers across…

Read MoreTavoron Strengthens Industrial Automation Portfolio with Acquisition of Fluidraulics

Charles River to Provide NGS Services to Arovella Therapeutics, Advancing Development of Innovative Cancer Therapies

Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches Charles River Laboratories International, Inc. announced a collaboration with Arovella Therapeutics Ltd a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS)…

Read MoreCharles River to Provide NGS Services to Arovella Therapeutics, Advancing Development of Innovative Cancer Therapies
CEL-SCI to Initiate FDA

CEL-SCI to Initiate FDA Registration-Enabling Phase 3 Confirmatory Trial for Multikine® in Newly Diagnosed Head and Neck Cancer

CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer CEL-SCI Corporation announced it is launching its global Confirmatory Registration Study of Multikine® (Leukocyte Interleukin, Injection)* as a neoadjuvant treatment…

Read MoreCEL-SCI to Initiate FDA Registration-Enabling Phase 3 Confirmatory Trial for Multikine® in Newly Diagnosed Head and Neck Cancer
Amprion and Modality.AI Break New Ground in Multimodal Assessment for Neurodegenerative Disease

Amprion and Modality.AI Pioneer a New Era in Multimodal Assessment for Neurodegenerative Disease

Amprion and Modality.AI Break New Ground in Multimodal Assessment for Neurodegenerative Disease Amprion, a global leader in the diagnosis of neurodegenerative disorders through seed amplification testing, and Modality.AI, a leader in AI-enabled multimodal clinical assessments, announced a collaboration to explore…

Read MoreAmprion and Modality.AI Pioneer a New Era in Multimodal Assessment for Neurodegenerative Disease
Immunomic Therapeutics

Immunomic Therapeutics Doses First Patient in Phase 1 Trial of Allergy Vaccine Candidate ITI-9001

HLB Subsidiary Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Allergy Vaccine Candidate ITI-9001 Immunomic Therapeutics Inc., a clinical-stage biotechnology company and a subsidiary of HLB, announced that the first participant has been dosed in the Phase…

Read MoreImmunomic Therapeutics Doses First Patient in Phase 1 Trial of Allergy Vaccine Candidate ITI-9001
Announce

Brenus Pharma Strengthens Governance with New President and Independent Board Appointment

Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member Brenus Pharma announced key appointments to its board of directors. The company welcomes Eric DESSERTENNE as President & Chairman of…

Read MoreBrenus Pharma Strengthens Governance with New President and Independent Board Appointment
Arima Genomics

Arima Genomics Partners with Active Motif to Expand Distribution of Research Hi-C Sequencing Kits and Services

Arima Genomics Announces Distribution Partnership with Active Motif for Research-Specific Hi-C Sequencing Kits and Services   Arima Genomics, Inc., a cancer diagnostics company bringing DNA sequence and structure together to advance cancer therapy selection, today announced a distribution partnership with…

Read MoreArima Genomics Partners with Active Motif to Expand Distribution of Research Hi-C Sequencing Kits and Services
Celea-Therapeutics

Celea Therapeutics Secures $180 Million to Advance Deupirfenidone for Idiopathic Pulmonary Fibrosis Treatment

Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF) Celea Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing transformative treatments for people with serious respiratory diseases, today…

Read MoreCelea Therapeutics Secures $180 Million to Advance Deupirfenidone for Idiopathic Pulmonary Fibrosis Treatment